The Hackensack University Medical Center Foundation has received a substantial donation from Celgene Corporation to advance multiple myeloma research and transformational medicine that improve patient outcomes at Hackensack Meridian Health – John Theurer Cancer Center.
Supported by Celgene, a global biopharmaceutical leader in the discovery, development and delivery of treatment for diseases like multiple myeloma (MM), funds will help to establish the Multiple Myeloma Institute (MMI) – a leading-edge research facility at the Seton Hall-Hackensack Meridian School of Medicine scheduled to open in 2018.
Celgene and John Theurer Cancer Center are accomplished leaders in developing novel therapies for patients with multiple myeloma. Advances in science in the last decade have increased survival for patients from three to 10 years. The Multiple Myeloma Institute will represent a true “clinical laboratory” that will aid patients by harnessing real-world, real-time clinical data that advances care.
“We seek to transform the treatment of patients with multiple myeloma by integrating our enormous clinical expertise at John Theurer Cancer Center with ongoing basic and translational research,” said Robert C. Garrett, co-CEO, Hackensack Meridian Health. “It is now time to leverage our shared vision, talents, and accumulated knowledge and expertise into a comprehensive Institute – an integrated clinical laboratory, and population science-based research center – that will exponentially advance our fight against multiple myeloma and accelerate a cure.”
“We’ve developed a true ‘clinical laboratory’ at John Theurer Cancer Center, and in our network, together with translational science and the Multiple Myeloma Institute, we will facilitate discovery in the field – while also monitoring progress at the population level,” said Andrew Pecora, MD, chief innovation officer and President of Physician Enterprise at Hackensack Meridian Health.
“The Multiple Myeloma Institute provides a unique opportunity to redefine the best standards, particularly the best sequence of care to improve patient outcomes,’’ Dr. Pecora said. “This could have an impact at scale in the global multiple myeloma community.”